FRANKLIN, Tenn., Nov. 28, 2011 (GLOBE NEWSWIRE) -- MedQuist Holdings Inc. (Nasdaq:MEDH), a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, announced today the continued enhancement of the company's senior management team with the addition of Matt Jenkins as the Senior Vice President of Corporate Business Development.
In his new role, Mr. Jenkins will be responsible for leading the company's development of strategic partnerships, including all aspects of inorganic growth such as acquisitions, investments and alliances. He brings a deep understanding of the healthcare information technology industry to MedQuist and a proven track record in successfully executing key transactions, relationships and developing high-growth strategies.
"Our development of an ecosystem of partners is helping us quickly expand our market access through an increased value proposition to customers and validates the strength of our cloud-based, context-enabled speech and natural language understanding technologies," said Vern Davenport, Chairman and Chief Executive Officer for MedQuist Holdings. "Matt's experience and associations within the industry will be instrumental in accelerating the execution of this strategy as we move into 2012 and beyond. He's an excellent addition to our senior leadership team."
Mr. Jenkins formerly led corporate development at Allscripts where he helped transform Allscripts through a period of dynamic growth, including the merger with Eclipsys in 2010, the 2008 merger with Misys Healthcare, the divesture of the Misys Hospital businesses in 2007 and several other transactions. As Vice President of Corporate Development and member of the Misys Healthcare operating board (Misys, plc) his responsibilities included developing the strategic plan for the portfolio and leading the formation of many partnerships and alliances. Mr. Jenkins has also held operational leadership roles in the ambulatory, acute, and post-acute business lines of Allscripts.
Prior to Allscripts, Mr. Jenkins was one of the three founding members of Cellective Therapeutics (acquired by AstraZeneca), a venture-funded biotechnology firm focused on developing industry-leading therapeutic antibodies for the treatment of oncology and immune-related diseases. His background also includes roles in the venture capital and consulting fields. Mr. Jenkins holds a Bachelor of Science in Business Administration and his MBA from University of North Carolina at Chapel Hill.
About MedQuist
MedQuist is a leading provider of clinical narrative capture services, Speech Understanding technology from M*Modal and clinical documentation workflow. MedQuist's enterprise solutions – including mobile voice capture devices, speech recognition, Web-based workflow platforms and global network of medical editors – help healthcare facilities facilitate adoption of electronic health records (EHR), improve patient care, increase physician satisfaction and lower operational costs. For more information, please visit www.medquist.com.
"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Photo available at http://ir.medquistholdings.com/index.php?s=142&item=72